".....but that ATL1102 modulates LTBP4 and Thrombospondin-1"
@waynesworld
Awesome to read terminology from the famous "proteomics" announcement...this ann might go down in ANP history as the company maker.
For new investors to the ANP story - i would highly recommend reading and re-reading the Proteomics ann which further explains the mechanisms of action of ATL1102.
Up until now it's been all about the Dystrophy indications: DMD, LGMD, Becker etc...but if we can pivot to something like "myocarditis" or other inflammatory settings like Asthma...
...then we await Godzilla to arrive on the scene, not a mere Gorilla in the mist
.
".....but that ATL1102 modulates LTBP4 and Thrombospondin-1"...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |